Group items tagged

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded Community pharmacy contractors to ensure that the correct flu vaccines are being used for each patient cohort. The pharmacies have also been asked to ensure that they recorded accurately in the patient's clinical record for the NHS Flu Vaccination Service. The move was followed by PSNC after the cases where the standard egg-cultured quadrivalent influenza vaccine (QIVe) was administered in the 65 years and over patient cohort. PSNC said: "On investigation, it appears that a number of these errors are due to data input errors; however, it is important to be careful when selecting a flu vaccine for this patient cohort as there is no provision for the use of the QIVe vaccine in patients aged 65 years and over in the NHS Flu Vaccination Service." The Joint Committee on Vaccination and Immunisation has advised it is not an effective intervention for patients aged 65 years and over.

Following discussions with Community Pharmacy Scotland, the Scottish government has agreed to a six per cent rise in the global fund allocation for community pharmacies in 2023-24, bringing the total remuneration to approximately £219.5 million. A finalised agreement has been reached with Community Pharmacy Scotland for a one-year funding package for the financial year 2023-24, as stated in a Scottish government circular distributed to community pharmacy contractors and NHS Boards on August 4. The circular said this settlement will lead to the most substantial increment ever approved for the community pharmacy network. "The global sum remuneration will be £219.533 million, signifying a 6 per cent increase from the previous year and setting the groundwork for 2024/25," stated Professor Alison Strath, Chief Pharmaceutical Officer for Scotland, in the document. "The guaranteed income from the drug tariff will remain at £80 million for the financial year, without yearly changes."

Pharmacy contractors will no longer need to print and submit a paper copy of their completed FP34C declaration made through the Manage Your Service (MYS) portal when submitting their paper prescription bundle to the NHS Business Services Authority (NHSBSA), said the Pharmaceutical Services Negotiating Committee (PSNC). Instead, from August 2022 (for July 2022 prescriptions), NHSBSA will post out a paper Account Identifier Document along with the red separators and pharmacy address labels each month. "The Account Identifier Document should be placed alongside the paper prescription bundle before it is dispatched for payment to the relevant pricing division of NHSBSA," said PSNC. With the help of Account Identifier Document, NHSBSA will be able to easily identify the pharmacy that has submitted the prescription bundle, which will help to speed up prescription processing. "If the Account Identifier Document is lost or misplaced, contractors will still be able to download and print another copy from MYS. The July 2022 Drug Tariff will be updated to reflect this change."

Pharmacy owners will be given additional time to claim for the provision of four services if IT issues, outside their control, prevent timely submissions. Effective February 2025, this provision applies to Hypertension Case-Finding, Pharmacy Contraception Service, Pharmacy First, and Smoking Cessation Services. Currently, claims must be submitted via the Manage Your Service (MYS) portal by the 5th of the following month, with late claims accepted only within three months of the actual submission date. Under the new rule, pharmacy owners will have an additional twelve months (from the date by which the claim should have been submitted) to claim payment if they can provide evidence of an IT issue beyond their control that delayed the claim submission. This new provision will be included in Part VIC of the February 2025 Drug Tariff, which will also have a clarification about de-registration from the four advanced services. The clarification will state that pharmacy owners who de-register from providing one of these services cannot re-register for four months after their 30-day notice period ends.

The National Pharmacy Association (NPA) has warned that it would go ahead with the planned collective action if consultations on the current financial year's funding do not commence this month and if a proposed deal fails to meet their minimum tests. New estimates from the NPA show that if collective action goes ahead, over 17,000 hours of pharmacy time per week could be lost to patients, totaling around 900,000 hours over the course of the year. The organisation has laid out five key tests that any funding package from the government must meet. It has demanded that the government and NHS England present an offer that meets rising costs, starts to bridge historic funding gaps and gives a roadmap to a sustainable financial future, along with reform of the broken Drug Tariff. Additionally, the NPA stated that the current system of pharmacy remuneration for medicine supply, which often results in dispensing at a loss, must undergo fundamental change as part of long-term reforms.

The price concession for Atorvastatin 80mg has been increased to £3.91 from the previously set £3.45 for prescriptions dispensed in July, the Community Pharmacy England has said. The Department of Health and Social Care additionally introduced a concession price of £3.38 for Atorvastatin 20mg. "In July, our Dispensing and Supply Team experienced an unusually high influx of reports from pharmacies struggling to acquire Atorvastatin 80mg tablets at the listed Drug Tariff price," said CPE. CPE requested a price concession early in the month. However, after extended discussions, an agreement on the price wasn't reached. Consequently, on July 31st, the DHSC imposed a concession of £3.45. Addressing enduring pharmacy concerns over the pricing, CPE intensified advocacy with DHSC. This endeavour resulted in the revision of the Atorvastatin 80mg tablet concession price to £3.91 for prescriptions submitted and dispensed in July. According to CPE, this adjusted price sufficiently covers costs as reported by the majority of pharmacy owners. However, DHSC has refrained from modifying concessionary prices for the other two requested lines by CPE. DHSC communicated that their team's data collection for July, employing real-time sales and volume data, was incongruent with the adjustment of these prices, CPE further said.